Katsaros D - Search Results

1

Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Lu L, et al. Among authors: katsaros d. Oncol Res. 2007;16(8):395-403. doi: 10.3727/000000006783980892. Oncol Res. 2007. PMID: 17913048

2

Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.

Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P. Yu H, et al. Among authors: katsaros d. Cancer Res. 1995 May 15;55(10):2104-10. Cancer Res. 1995. PMID: 7538047

3

Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.

Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Levesque MA, et al. Among authors: katsaros d. Cancer. 1995 Mar 15;75(6):1327-38. doi: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p. Cancer. 1995. PMID: 7882283

4

Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients.

Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis EP. Zarghami N, et al. Among authors: katsaros d. Br J Cancer. 1996 Feb;73(3):386-90. doi: 10.1038/bjc.1996.66. Br J Cancer. 1996. PMID: 8562347 Free PMC article.

5

Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma.

Zarghami N, Katsaros D, Yu H, Diamandis EP. Zarghami N, et al. Among authors: katsaros d. Can J Oncol. 1995 Sep;5(3):401-7. Can J Oncol. 1995. PMID: 8853514

6

Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.

Lianidou ES, Levesque MA, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis EP. Lianidou ES, et al. Among authors: katsaros d. Anticancer Res. 1999 Jan-Feb;19(1B):749-56. Anticancer Res. 1999. PMID: 10216487

7

[Chemoresistance in ovarian cancer. State of the art and future prospects].

Katsaros D, Fracchioli S, Arese P, Enria R, Cassinelli P, Mingrone K, Piccinno R, Rigault de la Longrais IA, Massobrio M. Katsaros D, et al. Minerva Ginecol. 1999 Dec;51(12):483-99. Minerva Ginecol. 1999. PMID: 10767997 Review. Italian.

8

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.

Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP. Levesque MA, et al. Among authors: katsaros d. Clin Cancer Res. 2000 Aug;6(8):3260-70. Clin Cancer Res. 2000. PMID: 10955812

9

IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival.

Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi MJ, Diamandi A, Gordini G, Diamandis EP, Massobrio M. Katsaros D, et al. Eur J Cancer. 2001 Mar;37(4):478-85. doi: 10.1016/s0959-8049(00)00423-8. Eur J Cancer. 2001. PMID: 11267857

10

Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.

Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP. Luo LY, et al. Among authors: katsaros d. Clin Cancer Res. 2001 Aug;7(8):2372-9. Clin Cancer Res. 2001. PMID: 11489815

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters